Antibodies against Oxidized Phospholipids and Osteoporosis

Studies will establish whether E06-scFv increases bone mass by increasing Wnt10b through characterizing the bone phenotype of E06-scFv transgenic mice crossed with mice in which Wnt10b has been globally deleted. It will also determine whether weekly injections of murine monoclonal E06 IgG increase bone mass and reproduce the anabolic effects of the E06-scFv transgene in young and old mice. Additionally, clinical studies will be expanded to determine whether the levels of anti-PC IgM correlate with baseline BMD, with longitudinal BMD changes in the elderly, and with fractures, by measuring these levels in large cohorts from the Osteoporotic Fractures in Men (MrOS) and the Study of Osteoporotic Fractures (SOF) in women.